Kymera Therapeutics Competitors

Kymera Therapeutics (NASDAQ:KYMR) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Kymera Therapeutics and Twist Bioscience, as provided by MarketBeat.

Kymera Therapeutics presently has a consensus price target of $48.6667, indicating a potential upside of 25.88%. Twist Bioscience has a consensus price target of $137.50, indicating a potential downside of 0.56%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kymera Therapeutics is more favorable than Twist Bioscience.

Valuation & Earnings

This table compares Kymera Therapeutics and Twist Bioscience's gross revenue, earnings per share and valuation.

Kymera Therapeutics has higher earnings, but lower revenue than Twist Bioscience.

Profitability

This table compares Kymera Therapeutics and Twist Bioscience's net margins, return on equity and return on assets.

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Kymera Therapeutics beats Twist Bioscience on 6 of the 9 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Earnings & Valuation

This table compares Denali Therapeutics and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Kymera Therapeutics has lower revenue, but higher earnings than Denali Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and target prices for Denali Therapeutics and Kymera Therapeutics, as provided by MarketBeat.

Denali Therapeutics currently has a consensus price target of $75.8571, suggesting a potential upside of 39.60%. Kymera Therapeutics has a consensus price target of $48.6667, suggesting a potential upside of 25.88%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Denali Therapeutics and Kymera Therapeutics' net margins, return on equity and return on assets.

Summary

Denali Therapeutics beats Kymera Therapeutics on 6 of the 9 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Profitability

This table compares Kymera Therapeutics and Halozyme Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Kymera Therapeutics and Halozyme Therapeutics' gross revenue, earnings per share and valuation.

Kymera Therapeutics has higher earnings, but lower revenue than Halozyme Therapeutics.

Institutional & Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 2.6% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Kymera Therapeutics and Halozyme Therapeutics, as provided by MarketBeat.

Kymera Therapeutics currently has a consensus price target of $48.6667, suggesting a potential upside of 25.88%. Halozyme Therapeutics has a consensus price target of $42.9167, suggesting a potential downside of 7.15%. Given Kymera Therapeutics' higher probable upside, research analysts clearly believe Kymera Therapeutics is more favorable than Halozyme Therapeutics.

Summary

Halozyme Therapeutics beats Kymera Therapeutics on 8 of the 9 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are held by institutional investors. 22.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Kymera Therapeutics and Adaptive Biotechnologies, as provided by MarketBeat.com.

Kymera Therapeutics presently has a consensus target price of $48.6667, suggesting a potential upside of 25.88%. Adaptive Biotechnologies has a consensus target price of $61.40, suggesting a potential upside of 46.71%. Given Adaptive Biotechnologies' higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Kymera Therapeutics.

Valuation & Earnings

This table compares Kymera Therapeutics and Adaptive Biotechnologies' gross revenue, earnings per share and valuation.

Kymera Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies.

Profitability

This table compares Kymera Therapeutics and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Summary

Kymera Therapeutics beats Adaptive Biotechnologies on 5 of the 9 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Profitability

This table compares Kodiak Sciences and Kymera Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

82.3% of Kodiak Sciences shares are held by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are held by institutional investors. 39.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Kodiak Sciences and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Kodiak Sciences and Kymera Therapeutics, as reported by MarketBeat.

Kodiak Sciences presently has a consensus target price of $129.9091, suggesting a potential upside of 14.39%. Kymera Therapeutics has a consensus target price of $48.6667, suggesting a potential upside of 25.88%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Kodiak Sciences.

Summary

Kymera Therapeutics beats Kodiak Sciences on 5 of the 7 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Vir Biotechnology and Kymera Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Vir Biotechnology and Kymera Therapeutics, as reported by MarketBeat.com.

Vir Biotechnology currently has a consensus price target of $66.00, suggesting a potential upside of 43.73%. Kymera Therapeutics has a consensus price target of $48.6667, suggesting a potential upside of 25.88%. Given Vir Biotechnology's higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Kymera Therapeutics.

Institutional & Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vir Biotechnology and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Kymera Therapeutics has lower revenue, but higher earnings than Vir Biotechnology.